Cosunter(SZ:300436) Zheng Quan Zhi Xing·2025-09-01 11:08Core Viewpoint - Fujian Guangshentang Pharmaceutical Co., Ltd. plans to transfer equity and increase capital in its subsidiary Guangsheng Zhonglin Biotechnology Co., Ltd. with a pre-investment valuation of 2.5 billion RMB, while the company will waive its preferential rights [1][3][20] Transaction Overview - The total investment amount for the capital increase is 191.35 million RMB, with Guangsheng Zhonglin's registered capital increasing from 388.5 million RMB to 418.236 million RMB [1][4] - The company will hold a 75.3163% stake in Guangsheng Zhonglin after the transaction, maintaining it as a controlled subsidiary [4][20] - The transaction requires approval from the shareholders' meeting [4] Investment Details - The investment will be made by Jinan Taishen Investment Partnership and Huaxin Shiheng, with respective contributions of 141.35 million RMB and 50 million RMB [3][20] - The equity transfer involves the sale of shares from Fuzhou Aotai Phase Five and Phase Six Investment Partnerships for a total of 58.65 million RMB [3][20] Financial Impact - The transaction aims to enhance Guangsheng Zhonglin's capital strength to support the development of innovative drugs, particularly for hepatitis treatment [20] - Guangsheng Zhonglin's innovative drugs GST-HG131 and GST-HG141 are included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [20] Strategic Importance - The transaction aligns with the company's strategy to accelerate the research and development of innovative drugs and improve its operational capabilities [20] - The company believes that the capital increase will help attract talent and enhance research efficiency, ultimately leading to the commercialization of core innovative products [20]